Results 1 to 10 of about 1,243 (80)

Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review [PDF]

Pharmaceutics, 2023
The actinium-225 (225Ac) radioisotope exhibits highly attractive nuclear properties for application in radionuclide therapy. However, the 225Ac radionuclide presents multiple daughter nuclides in its decay chain, which can escape the targeted site ...
Sipho Mdanda, Lindokuhle M. Ngema, Amanda Mdlophane, Mike M. Sathekge, Jan Rijn Zeevaart   +4 more
doaj   +2 more sources

Quality control of actinium-225 and 225Ac-radiopharmaceuticals: Francium-221 to be or not to be? [PDF]

EJNMMI Radiopharmacy and Chemistry
Background Actinium-225 radiopharmaceuticals have drawn great interest in cancer therapy due to their tumor-specific delivery of cytotoxic alpha-particles.
Miguel Toro-Gonzalez, Luke Wheeless, Vijai Kumar Reddy Tangadanchu, Cory Hawkins, Shannon Provo, William Smith, Michael Hommen, Dan DeVries, Jim Harvey, Tyler Drum, Diane S. Abou   +10 more
doaj   +2 more sources

Efficacy and Safety of Radioligand Therapy with Actinium-225 DOTATATE in Patients with Advanced, Metastatic or Inoperable Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis [PDF]

Medicina
Background and Objectives: Peptide receptor radionuclide therapy (PRRT) using radiopharmaceuticals labelled with Lutetium-177 is currently a therapeutic option for patients with advanced neuroendocrine neoplasms overexpressing somatostatin receptors ...
Alessio Rizzo, Alessio Imperiale, Salvatore Annunziata, Roberto C. Delgado Bolton, Domenico Albano, Francesco Fiz, Arnoldo Piccardo, Marco Cuzzocrea, Gaetano Paone, Giorgio Treglia   +9 more
doaj   +2 more sources

Actinium-225 in Targeted Alpha Therapy [PDF]

Journal of Medical Physics
The utilization of actinium-225 (225Ac) radionuclides in targeted alpha therapy for cancer was initially outlined in 1993. Over the past two decades, substantial research has been conducted, encompassing the establishment of 225Ac production methods ...
A. K. M. Rezaur Rahman, Mahathe Hasan Babu, Mustofa Khalid Ovi, Md. Mahiuddin Zilani, Israt Sultana Eithu, Amit Chakraborty   +5 more
doaj   +2 more sources

Pathogen-Specific Actinium-225 and Lutetium-177 Labeled Antibodies for Treatment of Biofilm-Associated Implant Infections: Initial In Vivo Proof-of-Concept [PDF]

Antibiotics
Background: the primary challenge with implant infections is the formation of biofilm, which harbors dormant bacteria that reduce the effectiveness of antibiotics and amplify antibiotic resistance, exacerbating the global antimicrobial resistance crisis.
F. Ruben H. A. Nurmohamed, Kevin J. H. Allen, Mackenzie E. Malo, Connor Frank, J. Fred F. Hooning van Duvenbode, Berend van der Wildt, Alex J. Poot, Marnix G. E. H. Lam, Jos A. G. van Strijp, Peter G. J. Nikkels, H. Charles Vogely, Harrie Weinans, Ekaterina Dadachova, Bart C. H. van der Wal   +13 more
doaj   +2 more sources

Evaluation of Actinium-225 Labeled Minigastrin Analogue [²²⁵Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy [PDF]

Pharmaceutics, 2020
The overexpression of cholecystokinin B receptor (CCKBR) in human cancers led to the development of radiolabeled minigastrin analogues for targeted radionuclide therapy, which aims to deliver cytotoxic radiation specifically to cancer cells.
Yun Qin, Stefan Imobersteg, Alain Blanc, Stephan Frank, Roger Schibli, Martin P. Béhé, Michal Grzmil   +6 more
doaj   +2 more sources

CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma [PDF]

OncoImmunology, 2021
Multiple myeloma (MM) is a hematological malignancy characterized by the presence of clonal plasma cells in the bone marrow niche. Despite significant therapeutic advances, MM remains incurable for the majority of patients. Targeted radionuclide therapy (
Kim De Veirman, Janik Puttemans, Ahmet Krasniqi, Thomas Ertveldt, Heleen Hanssens, Ema Romao, Dirk Hose, Cleo Goyvaert, Philip Vlummens, Serge Muyldermans, Karine Breckpot, Frank Bruchertseifer, Alfred Morgenstern, Matthias D’Huyvetter, Nick Devoogdt   +14 more
doaj   +2 more sources

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists [PDF]

Frontiers in Medicine, 2022
Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding clinical applications. By chelating a radiometal to a somatostatin receptor (SSTR)
Mengqi Shi, Mengqi Shi, Vivianne Jakobsson, Vivianne Jakobsson, Lukas Greifenstein, Pek-Lan Khong, Pek-Lan Khong, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Richard P. Baum, Jingjing Zhang, Jingjing Zhang, Jingjing Zhang   +15 more
doaj   +2 more sources

Astatine-211 and actinium-225: two promising nuclides in targeted alpha therapy [PDF]

Acta Biochimica et Biophysica Sinica
Nuclear medicine therapy offers a promising approach for tumor treatment, as the energy emitted during radionuclide decay causes irreparable damage to tumor cells. Notably, α-decay exhibits an even more significant destructive potential. By conjugating α-
Zuo Dashan, Wang Hui, Yu Boyi, Li Qiang, Gan Lu, Chen Weiqiang   +5 more
doaj   +2 more sources

Real-time trajectory imaging of alpha particles emitted from actinium-225 and its daughter radionuclides [PDF]

Scientific Reports
In targeted alpha-particle therapy, actinium-225 (Ac-225) has emerged as a radionuclide of potential, driving extensive efforts to develop innovative radiopharmaceuticals.
Seiichi Yamamoto, Masao Yoshino, Kenji Shirasaki, Kohei Nakanishi, Kei Kamada, Akira Yoshikawa, Jun Kataoka   +6 more
doaj   +2 more sources